Internal Medicine Alert – January 30, 2015
January 30, 2015
View Issues
-
Nonsteroidal Anti-inflammatory Drug Use and Risk of Atrial Fibrillation
SYNOPSIS: Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of incident atrial fibrillation, especially among new users of NSAIDs.
-
Should Metformin Use In Patients With Chronic Kidney Disease Be Expanded?
SYNOPSIS: Expansion of the metformin label to include patients with mild-to-moderate kidney disease is appropriate.
-
Can Intracardiac Echo Be Used as a Substitute for Transesophageal Echo Prior to Atrial Fibrillation Ablation?
This article originally appeared in the January 2015 issue of Clinical Cardiology Alert.
-
Ombitasvir, Paritaprevir, and Ritonavir, Dasabuvir Tablets (Viekira™ Pak)
The FDA has approved the fourth new product for the treatment of chronic hepatitis C (HCV) infection since November 2013. The latest is a four fixed-drug combination (3-DAA) that includes paritaprevir, a nonstructure 3/4A protease inhibitor, ombitasvir, an inhibitor of the NS5A replication complex, and copackaged with dasabuvir, a nonnucleoside NS5B polymerase inhibitor. The plasma levels of paritaprevir is boosted with ritonavir, a CYP3A inhibitor to permit once-daily dosing. The combination is marketed by AbbVie, Inc. as Viekira Pak.
-
Clinical Briefs
The Heavy Emotional Costs of Rosacea, Treatment Choices Among the PDE5 Inhibitors, and Screening Asymptomatic Diabetics with CT angiography